Buffett’s Surprising Stock Pick: UnitedHealth Group

by

Thursday, the 14th of August, might have passed with the quiet dignity of a well-attended tea party to the unobservant eye, yet for those attuned to the subtleties of Wall Street’s unspoken codes, it marked a moment of considerable consequence. While quarterly earnings reports often command the spotlight, it is the Form 13F filings-those discreet missives from institutional investors-that truly illuminate the dance of capital and cunning.

This particular quarterly performance, due no later than the 14th day of August, offered a glimpse into the portfolios of those entrusted with £100 million or more. It revealed, in careful strokes, the stocks that had been added to or subtracted from by the most esteemed stewards of wealth.

Among these stewards, none commands more attention than Mr. Warren Buffett, the Oracle of Omaha. His transactions, much like the movements of a celebrated hostess at a ball, are scrutinized with a mix of admiration and envy. To mirror his choices is to dance to the same tune of prudence and patience.

This quarter’s 13F, however, was marked by an air of mystery. For the first time in many years, the Oracle had employed the “confidential treatment” tag-a rare privilege allowing one to build a position in secrecy, much like a suitor composing a letter before its delivery. This discretion, it seemed, had been reserved for a stock that would leave Wall Street’s most astute observers in a state of bewilderment.

Confidential Treatment and the Art of Discretion

Regulators, ever mindful of the delicate balance between transparency and strategy, occasionally grant prominent investors this cloak of invisibility. The logic is as sound as it is pragmatic: to allow a gentleman of Buffett’s stature to accumulate shares without the immediate clamor of imitators. After all, a sudden surge in demand, precipitated by public knowledge, might render the acquisition rather less advantageous than it ought to be.

Mr. Buffett’s prior use of this privilege has been a subject of polite speculation. In 2015, he employed it to cultivate a stake in Phillips 66. During the tumult of the pandemic, he acquired Verizon Communications and Chevron, the latter of which remains a steadfast companion in his portfolio. More recently, he turned his attention to Chubb, the property & casualty insurer. And now, in the first half of 2025, the veil has been lifted to reveal his latest acquisition.

The quarterly operating reports of Berkshire Hathaway, much like the guest lists of a grand assembly, had offered faint clues as to the identity of this mystery stock. The cost basis of financial and consumer goods had declined, while the “commercial, industrial and other” category had risen. It was evident to those who observed closely that the Oracle’s interest lay not in the familiar realms of finance or staples, but in an altogether different sphere.

Indeed, his aversion to the fickle charms of technology and healthcare-sectors requiring a dexterity with which he has long been unacquainted-had narrowed the possibilities. The industrial sector, one might have assumed, was the likely suitor. But as it transpired, the Oracle’s choice was as unexpected as a quadrille at a country ball.

The Revelation of the Oracle’s Choice

Despite his reputation as a net seller for eleven consecutive quarters-having divested no less than $177.4 billion-Mr. Buffett’s June 2024 quarter revealed six new positions, with several existing holdings augmented. Yet it was the unveiling of his mystery stock that would stir both curiosity and consternation among his peers.

The stock in question, it turns out, is UnitedHealth Group. A sum of 5,039,564 shares, valued at nearly $1.6 billion, was acquired under his watchful eye. For those who have long presumed the Oracle to favor financial institutions, this choice was as jarring as a gentleman proposing to a lady he had never before met.

UnitedHealth’s business, though ostensibly in healthcare, shares a kinship with the insurance sector-a domain with which Mr. Buffett is intimately familiar. The company’s Medicare Advantage segment, while currently burdened by unforeseen costs, is not without its merits. Its Optum division, with its array of services and software, offers a margin and growth profile that might well appeal to one who prizes both stability and innovation.

Loading widget...

Mr. Buffett’s strategy, as ever, is one of patience and discernment. In a market where value has been elusive, the 54% decline in UnitedHealth’s stock since April presented an opportunity as rare as a well-timed dance at a crowded ball. The company’s forward P/E ratio of 14, a 26% discount to its five-year average, suggests that even in adversity, there is a certain elegance to the bargain.

Though the Oracle’s choice may have surprised the assembled observers, it is not without its logic. UnitedHealth Group, with its robust dividend and buyback program, offers the sort of capital preservation and return that aligns with the principles of a man who has built an empire on the virtues of prudence and restraint.

In the end, the Oracle’s selection is a reminder that even the most seasoned of investors must occasionally venture beyond the familiar. And as for Wall Street, it would do well to remember that the most unexpected matches are often the most enduring. 😊

Read More

2025-08-17 10:12